非小细胞肺癌抗血管生成治疗药物和策略  

Strategy of anti-angiogenesis and antiangiogenic drugs in NSCLC

作　　者：赵向飞[1] 聂青[1] 康静波[1] 

机构地区：[1]海军总医院放射肿瘤科,北京100048

出　　处：《国际肿瘤学杂志》2012年第12期916-920,共5页Journal of International Oncology

摘　　要：非小细胞肺癌发生、发展及转移与血管生成密切相关，肺癌抗血管药物分为抗血管内皮生长因子（VEGF）单抗、小分子抑制剂、肿瘤血管生成干扰剂、内皮细胞生成抑制剂等，多个临床试验研究显示抗血管生成药物较传统药物在疗效方面有生存优势，而抗血管生成药物与传统治疗方式联合的治疗策略也在逐渐探索。Development and metastasis of NSCLC are closely related to angiogenesis. Several distinct groups of vascular-targeted therapies have evolved： anti-VEGF monoclonal antibody, small molecules inhibi- tots, vascular disrupting agents, endothelial cell growth inhibitors, et al. Antiangiogenic treatment could make longer survival than conventional treatment. The strategy of anti-angiogenic drugs combined conventional treat- ment is being studied.

关 键 词：癌 非小细胞肺 血管生成抑制剂 分子靶向治疗 

分 类 号：R734.2[医药卫生—肿瘤]